Dr. Siddharth Sharma

Associate Professor

Specialization

Cancer Biology

Email

siddharthsharma.phd@thapar.edu

Specialization

Cancer Biology

Email

siddharthsharma.phd@thapar.edu

 Siddharth Sharma, PhD

Associate Professor

Department of Biotechnology                                              E-mail: siddharthsharma.phd@thapar.edu

Thapar Institute of Engineering and Technology, Patiala       Contact no: 9501688366

 

Research Interest

  • SNP related Risk assessment, Cancer Biomarker discovery, Polymorphism relation to cancer susceptibility and clinical outcomes.
  • Molecular markers for lung cancer prognosis, Protein Microarrays
  • Genetics of pulmonary diseases like COPD and asthma
  • Inflammation and chronic disease

Educational Qualification

  • Ph.D (Cancer Genetics):  Panjab university, Chandigarh (2004)
  • M.Sc (Life Sciences): School of Life Sciences, Pondicherry University (1998)
  • B.Sc (Botany): Madras University (1996)

 

Position and Employment (Starting with the most recent employment)

S. No.

Institution

Place

Position

From (Date)

To (date)

1

Department of Biotechnology, Thapar Institute of Engineering & Technology

Associate Professor

July 2017

Till date

2

Department of Biotech and Environment Sciences, Thapar University

Assistant Professor

July 2011

July 2017

3.

Beckman Coulter Pvt. Ltd

Application Scientist

August 2009

June 2011

4.

Department of Pathology, Miller School of Medicine, University of Miami Florida, USA

Postdoctoral Research Fellow

January 2007

June 2009

5.

Department of Molecular and cellular biology University of Cape Town

Postdoctoral Research Fellow

January 2005

Nov 2006

6.

Ranbaxy Research Laboratory, Gurgaon

Research Scientist

June 2004

Nov 2004

7.

NIPER, Mohali

Research Associate

(Scientist Grade II)

Sept 2002

June 2004

 

 

 

 

 

 

 

 

 

 

Research Summary

 

Dr Siddharth Sharma, Associate Professor in Biotechnology, T.I.E.T has completed his undergraduate and post-graduate studies in Life Sciences from prestigious Institutes like University of Madras and Central University, Pondicherry. He then completed his doctoral studies in the area of Cancer genetics from Panjab University. His doctoral work won him the young scientist award in 2002 from Panjab Academy of Sciences.  After completion of his Ph.D he joined National Institute of Pharmaceutical and Educational Research (NIPER), Mohali as a Research Associate (Scientist Grade II) where he worked in the area of aging. After his stint in NIPER he joined Ranbaxy Laboratories as a research Scientist where he was involved in cloning and expression of Muscarinic receptors. To further hone his skills in research he joined as a post-doctoral fellow in the Institute of Infectious diseases and Molecular Medicine University of Cape Town and worked in the area of protein Microarrays of drug metabolizing genes, his Post-doctoral Fellow ship was sponsored from Procognia Limited a London based biotechnology company. After his completion of post-doctoral studies in Cape Town, he moved to USA and was appointed as post-doctoral fellow in the department of Pathology, Miller School of Medicine, University of Miami, USA. He worked in the area of hematopoietic stem cells. Dr Sharma, after completion of his PDF in USA joined as an application scientist in Beckman Coulter where he was involved in training on Flow Cytometry to scientists. In 2011 Dr Sharma joined Thapar Institute of Engineering and Technology as an assistant professor.

 

 

Current Research

Our research is focused on Genomic profiling of lung cancer – a) Risk assessment (b) Biomarker expression related especially clinical outcomes (c) Toxicogenomics in lung cancer (d) Genetic variants in signalling pathways and its role in pathogenesis of lung cancer (e) Genetics of COPD and Asthma

(a) Our primary area of research is related to the molecular epidemiology of lung tumors in North Indian population. Since genetic background has an important role in susceptibility to complex diseases, our work has helped us to identify key Single Nucleotide Polymorphism (SNPs) which are associated with individual susceptibility for lung carcinogenesis. Secondly, we have also identified the role of polymorphic variants of certain genes and their synergistic interaction with environmental stimuli. Thus, we are better able to understand the mechanisms through which environmental exposure interacts with cancer susceptibility genes which might open up new avenues for disease prevention. Current efforts are focused on polymorphisms in genes involved in DNA synthesis and repair. We have used a comprehensive genomic approach to assess the role of DNA repair capacity (DRC) in lung cancer etiopathogenesis and performed lung cancer risk assessment in hospital-based case–control studies. Our work has led us to the identification of interaction between tobacco smoke exposure and genetically susceptible subgroups that cause disease. This could further lead to the development of public health programs for protecting susceptible populations, and for targeted screening of groups at higher risk of disease.

(b) Another area of research where we are focusing is the role of SNPs and clinical outcomes in lung cancer patients. Lung cancer is the most common cancer amongst male malignancy and the overall survival rates are quite poor. Our primary area of research has been single nucleotide polymorphisms and tumor biomarkers and their correlation with treatment (Chemotherapy) outcomes and prognosis. Single nucleotide polymorphisms (SNPs) are one of the potential molecular markers that shall help us identify patients with unfavorable prognostic factors as well as those with poor response to chemotherapy, and therefore it might help in the selection of an appropriate chemotherapy regimen in the adjuvant and metastatic setting. We have identified SNPs of genes involved in the multistep processes of cancer genesis and the metabolism of chemotherapy that might prove clinically significant

 

(c) Recently our group has also delved in the area of the role of polymorphisms in relation to pharmacogenetics applications and personalized cancer therapy.  Since most of the chemotherapeutic agents for cancer treatment affect a minority of cancer patients and have a narrow therapeutic index that frequently causes life-threatening toxicities and even death. Thus, novel treatment strategies that can increase the effectiveness of therapy and decrease the rate of adverse events will be developed. We have identified SNPs of genes involved in playing an important role in profiling the toxicity of lung cancer patients undergoing chemotherapy. Under this approach, the aim of personalized medicine is to tailor the therapy options according to patient’s molecular profile.

(d) We have studied the role of genetic variations in the Wnt and AhR signalling pathway and evaluated its effect on lung cancer risk in North Indians. Our study is a primary effort to introduce the concept of polygenic approach to get an insight about the various polymorphic variants in determining cancer susceptibility. Our findings might help in the establishing the influence of genetic variants in the Wnt signaling pathway genes and its role towards lung carcinogenesis.

 Dr siddharth has active research collaborations with Department of Pulmonary Medicine PGIMER, Chandigarh and also with Rajindra Medical college and Hospital Patiala. He has published 45 research papers in international Journals of repute.

 

RESEARCH ACCOMPLISHMENTS

  1. SPONSORED RESEARCH PROJECTS COMPLETED: 48 lacs INR from Govt. agencies.
  2. DEVELOPED –Collaborative research projects with Department of pulmonary medicine, PGIMER, Chandigarh and Rajindra Medical college, Patiala
  3. Leading an independent research group in the area of Lung cancer Biomarker discovery, Etiopathogenesis of lung and breast cancer
  4. Scientific contribution includes >47 peer reviewed international publications (SCI); 4 Book chapters
  5. Research networking: Department of pulmonary medicine, PGIMER, Chandigarh and Department of Pathology, Rajindra Medical college, Patiala

 

                             Ph.D. and Graduate students (from all sources) working at present with the mentor

Thesis supervision

Completed

Ongoing

Thesis submitted

PhD

5

6

 

DM

1

 

 

MD

2

2

 

M.Tech

10

1

 

M.Sc

27

2

 

 

 

  • Publications of Dr. Siddharth Sharma (PI) (SCI Only)
  • Total Impact factor=124
  • Avg impact factor=2.68

 

 

 

  1. Harleen Kaur Walia, Navneet Singh, Siddharth Sharma. 2021. NQO1 polymorphism with clinical outcomes and survival of lung cancer patients treated with platinum chemotherapy Personalized Medicine (In press) (IF=2.512)
  2. Ankan Bandyopadhyay, Siddharth Sharma, Digambar Behera, Navneet singh. 2021. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan‚ÄźPlatinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall survival. The Oncologist. (In press) doi: 10.1002/onco.13757. (IF=5.01)
  3. Harleen Kaur Walia, Ushina Verma, Navneet Singh, Siddharth Sharma. 2019.Polymorphisms in GSTM1 and GSTT1 influence response and treatment outcome in lung cancer patients treated with platinum-based chemotherapy. British Journal of Biomedical Science 4:198-200 (IF=3.829)
  4. Shweta Lawania, Navneet Singh, Digambar Behera & Siddharth Sharma. 2019. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian Patients treated with platinum-based doublet chemotherapy. Future oncology 15(2)151-165 (IF=3.404)
  5. Amrita singh, Navneet Singh, Digambar Behera & Siddharth Sharma. 2019. XRCC1 632 as a candidate for cancer predisposition via a complex interaction with genetic variants of base excision repair and double strand break repair genes. Future Oncology. 10.2217/fon-2019-0297. (IF=3.404)
  6. Shweta Lawania, Amrita singh, Navneet Singh, Digambar Behera & Siddharth Sharma. 2019. The multi-faceted high order polymorphic synergistic interactions among nucleotide excision repair genes increase the risk of lung cancer in North Indians. Mutat Res Fund Mol Mech Mutagen. 816-818 (IF=2.1)
  7. Noorpreet I. Dhanjal, Siddharth Sharma, Anatoly V. Skalny, Margarita G.Skalnaya, Olga P. Ajsuvakova, Alexey A. Tinkov, Feng Zhang, Xiong Guo,K. Sandeep Prabhu and N. Tejo Prakash. 2019. Selenium-rich maize modulates the expression of prostaglandin genes in lipopolysaccharide stimulated RAW264.7 macrophages. Food and Function 10:2839-2846(IF=5.396)

 

  1. S. Singh, R.S. Kaler and S. Sharma. 2019. FEM simulation analysis of fiber optic surface plasmon resonance sensor based on array of circular gold nanorod. Journal of Nanoelectronics and Optoelectronics 14(5) 669-674 (IF=1.069)
  2. S. Singh, R.S. Kaler and S. Sharma. 2019. Resonance Effect of Bimetallic Diffraction Grating on the Sensing Characteristics of Surface Plasmon Resonance Sensor with COMSOL Multiphysics Journal of Nanoelectronics and Optoelectronics. 14,pp. 1–6 (IF=1.069)
  3. S. Singh, R.S. Kaler and S. Sharma. 2018. A Novel Two-Dimensional Material Based Optical Fiber Surface Plasmon Resonance Sensor for Sensing of Organic Compounds in Infrared Spectrum Window. Journal of Communications Technology and Electronics, 63:1269-1275 (IF=0.529)

 

  1. Charu Bahl, Navneet Singh, Digambar Behera, Navneet Singh, Digambar Behera & Siddharth Sharma 2018. Genetic variants in Wnt antagonist genes predicts the overall survival and prognosis of North Indian lung cancer patients treated with platinum-based doublet chemotherapy. Cancer Biotherapy and Radiopharmaceuticals. 33:1-10. (IF=3.099)
  2. Shweta Lawania, Navneet Singh, Digambar Behera & Siddharth Sharma. 2018. Association of XPA Polymorphisms Towards Lung Cancer Susceptibility and its Predictive Role in Overall Survival of North Indians.   Biochemical Genetics. 56 (4): 375-396 (IF=1.89)
  3. Amrita Singh, Navneet Singh, Digambar Behera & Siddharth Sharma. 2018. Role of polymorphic XRCC6 (Ku70/ XRCC7 (DNAPKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum-based doublet chemotherapy. Molecular Biology Reports.  45(3):253-261. (IF=2.316)
  4. Shweta Lawania, Navneet Singh, Digambar Behera & Siddharth Sharma. 2018. XPF polymorphism toward lung cancer susceptibility and survival in patients treated with platinum-based chemotherapy. Future Oncology. 14(11):1071-1089 (IF=3.404)
  5. Apurva Bhardawaj, Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma. 2018. Interactive potential of genetic polymorphism in Xenobiotic metabolizing and DNA repair genes for predicting lung cancer predisposition and overall survival in North Indians. Mutation Research and Genetic Toxicology. 826:15-24. (IF=2.873)
  6. Sneha, Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma. 2018. Role of sequence variations in AhR gene towards modulating smoking induced lung cancer susceptibility and Clinical outcomes in North Indian population: A multiple interaction analysis. Current Genomics. 19: 313-326. (IF=2.23)
  7. Amrita Singh, Navneet Singh, Digambar Behera, Siddharth Sharma. 2017. Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Pathology & Oncology Research. doi:10.1007/s12253-017-0372-6. (IF=3.20)
  8. Ankita Pandey, Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma.2017. Functional role of CyclinD1 polymorphism (G870A) in modifying susceptibility and overall survival of North Indian lung cancer patients. Tumori. 104(3): 179-187. (IF=2.098)
  9. Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma. 2017. High order gene interactions between the genetic polymorphisms in Wnt and AhR pathway towards lung cancer susceptibility. Personalized Medicine. 14(6): 487-502. (IF=2.512)
  10. Shweta Lawania, Navneet Singh, Digambar Behera & Siddharth Sharma. 2017. XPD polymorphism towards lung cancer susceptibility survival and response in patients treated with platinum chemotherapy. Future Oncology. 13(22): 1945–1965. (IF=3.404)
  11. Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma. 2017. Single Nucleotide Variations in the Wnt antagonist sFRP3 (rs7775 & rs288326) and sFRP4 (rs1802073 &1802074) genes and their association with lung cancer risk in North Indians. Meta Gene. 13: 159-168
  12. Shweta Lawania, Navneet Singh, Digambar Behera & Siddharth Sharma. 2017. XPC Polymorphism and risk for lung cancer in North Indian patients treated with platinum-based chemotherapy and its association with clinical outcomes. Pathology & Oncology Research. 24(2) 353-366. (IF=3.20)
  13. Amrita Singh, Navneet Singh, Digambar Behera & Siddharth Sharma. 2017. Polymorphism in XRCC1 gene modulates survival and clinical outcomes of Advanced North Indian Lung cancer patients treated with platinum-based doublet chemotherapy. Medical Oncology. 34 (4): 64-78. (IF=3.064)
  14. Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma. 2017. Association of candidate genetic variations in Axin2 gene with lung cancer risk in North Indian population: A multiple-interaction analysis. Tumor Biology. 39:1:18. (IF=3.65)
  15. Noorpreet Dhanjal, Siddharth Sharma, Suresh Prabhu, N Tejo Prakash. 2017. Selenium supplementation through Se-rich dietary matrices can upregulate the anti-inflammatory responses in lipopolysaccharide-stimulated murine macrophages. Food and Agricultural Immunology. 28:(6):1374-1392. (IF=3.10)

 

  1. Vijay Kumar Bodal, Shruti Sangwan, Manjit Singh Bal , Mohanvir Kaur , Siddharth Sharma, Bhavleen Kaur. 2017.  Association between Microrna 146a and Microrna 196a2 Genes Polymorphism and Breast Cancer Risk in North Indian Women. Asian Pacific Journal of Cancer Prevention. 18 2345-2348.
  2. Amrita Singh, Navneet Singh, Digambar Behera & Siddharth Sharma. 2016. Association and multiple interaction analysis among five XRCC1 polymorphic variants in modulating lung cancer risk in North Indian population. DNA Repair. 47: 30–41. (IF=4.91)
  3. Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma. 2016. Association of polymorphisms in Dickopff (DKK) gene towards modulating risk for lung cancer in north Indians. Future Oncology. 13 (3) 213-232. (IF=3.404)
  4. Ankita Kumar, Charu Bahl, Navneet Singh, Digambar Behera & Siddharth Sharma. 2016.  Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy. Molecular Biology Reports. 43:1383–1394. (IF=2316)
  5. Yashila Girdhar, Navneet Singh, Digambar Behera & Siddharth Sharma.  2016. Synergistic association of CYP1A1 polymorphisms with increased susceptibility to squamous cell lung cancer in north Indian smokers. Int J Biol Markers. 31(4): e402-e412. (IF=2.66)
  6. Girdhar Y, Navneet Singh, Behera D, Siddharth Sharma. 2016.   Combinations of the variant genotypes of CYP1A1, GSTM1 and GSTT1 are associated with an increased lung cancer risk in North Indian population: a case-control study. Pathology & Oncology Research. 22(3): 647-652. (IF=3.20)
  7. Noorpreet I. Dhanjal, Siddharth Sharma, and N. Tejo Prakash.2016. Quantification and In Vitro Bioaccessibility of Selenium from Osborne Fractions of Selenium-Rich Cereal Grains. Cereal Chemistry 93 (4): 339-343 (IF=1.984)

 

  1. Saronika Jindal, Shruti Sobti; Mukesh Kumar; Siddharth Sharma; Manoj Kumar Pal.2016. Nanocavity-Coupled Photonic Crystal Waveguide as Highly Sensitive Platform for Cancer Detection.  IEEE Sensors Journal. 16 (10): 3705-3710 (IF=3.30)

 

  1. Sharma N, Singh A, Singh N, Behera D, Sharma S. 2015. Genetic polymorphisms in GSTM1, GSTT1 and GSTP1 genes and risk of lung cancer in a North Indian population. Cancer Epidemiology. 39(6): 947-955. (IF=2.984)
  2. Sodhi KK, Bahl C, Singh N, Behera D, Sharma S. 2015. Functional Genetic Variants in pre-miR-146a and 196a2 genes are associated with risk of lung cancer in North Indians. Future Oncology. 11(15): 2159-2173. (IF=3.404).
  3. Siddharth Sharma, Shariatmadar Sherry; Krishan Awtar.2010. Electronic Volume, Aldehyde dehydrogenase and Stem Cell Marker Expression in Cells from Human Peripheral Blood Apheresis Samples. Cytometry B (Clinical Cytometry). 78B; 123-129. (IF=3.058).

 

  1. Krishan Awtar, Deepti Sharma, Siddharth Sharma, Ron Hamelik, Parvin Ganjei- Azar, Mehrdad Nadji. 2010. ALDH+/CD44+/CD24- Expression in Cells from Body Cavity Fluids. Clinical Cytometry (Cytometry B) 78B: 176-182 (IF=3.058).

 

  1. Siddharth Sharma; Cabana Raquel; Shariatmadar Sherry; Krishan Awtar. 2008. Cellular volume and marker expression in human peripheral blood apheresis stem cells. Cytometry Part A. 73(2): 160-16 (IF=4.355).

 

  1. Shariatmadar Sherry;  Siddharth Sharma; Cabana  Raquel;  Powell  Scott;  Ruiz Phillip; Krishan Awtar. 2008. Electronic volume of CD34 positive cells from peripheral blood apheresis samples.Cytometry. Part B, Clinical Cytometry. 74 (3): 182-188. (IF=3.058).

 

  1. S. Agarwal*, S. Sharma*, V. Agarwal and N. Roy*both authors contributed equally. 2005.Caloric Restriction Augments ROS Defense in S. cerevisiae, by a Sir2p Independent Mechanism. Free Radical Research 39:55-62. (IF=4.148).

 

  1. R.C. Sobti, A.I. Al-Badran, S. Sharma, S.K. Sharma, A. Krishan, H. Mohan. 2005. Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India. Cancer Genetics and Cytogenetics. 156; 68–73. (IF=2.523)

 

  1. Sobti, R.C, Sharma, S, Jindal; 5K., and Janmeja; A. 2004. Genetic polymorphism of the CYP1A1, CYP2ET, GSTMI and GSTTI genes and lung cancer susceptibility in North Indian population. Molecular & Cellular Biochemistry. 266: 1-9. (IF=3.396)

 

  1. Sobti, R.C, Sharma, S, Joshi, A., Jindal, S.K., Janmeja, A. 2003. CYPIAI and CYP2D6 polymorphism and risk towards lung cancer in a North Indian population. Biomarkers. 8(5): 415-428. (IF=2.568)

 

  1. Gill, T., Sharma, V., Mamtesh, Sharma, S., Sobti, R.C. 2003. RAPD-PCR analysis in two species of Catopsilia. Carologia 56: 100-105. (IF=1.214)

 

  1. RC Sobti, S Sharma. 2001. Molecular genetics of cancer with special reference to cancers of GI tract, Lung, Head and Neck and Cervix. JPAS. 1: 63-67.
  2. RC Sobti, S Sharma. 2000 Molecular markers in lung cancer. Nucleus. 43(1,2):71-82.

 

  1. Anand Manju, Sharma Siddharth, Monga Preetika. 2020. Antimicrobial and antioxidant potential of Tylophora indica (Burm. f.) Merrill and development of an efficient micropropagation system for its therapeutic use Medicinal Plants - International Journal of Phytomedicines and Related Industries. 12(1) 82-89.

 

 

Research Projects

Details of Projects completed during the last 5 years

S. No

Title

Cost in Lakh

Duration

Role as PI/Co-PI

Agency

1

Association of single nucleotide polymorphisms and methylation status in the wnt and ahr signaling pathways with risk for occurrence of lung cancer in North Indians

27.5

2012-2015

PI

I.C.M.R, New Delhi

2

Studies on anti-inflammatory responses as function of bioavailable selenium from Se-rich cereal grains

19.92

2012-2015

Co-PI

C.S.I.R, New Delhi

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Book Chapters:

 

1.  Siddharth Sharma and Awtar Krishan. Electronic Volume of Hematopoietic Stem Cells. In:Flow Cytometry Applications in Stem Cell Research, Eds. Awtar Krishan, H Krishnamurthy and Satish Totey, John Wiley-Blackwell Publications; 2010.

 

2. Molecular genetics of Gastrointestinal Tract Cancers. (2002). In book:Some aspects of Chromosome Structure and Function. Pp 177-1 92 (Eds) Sobti, R.C. eta!. Publishers (Kluwer & Narosa).

 

3. Telomere Telomerase and Cancer. (2002), In book: Some aspects of Chromosome Structure and Function. pp 168-191 (Eds) Sobti, R.C. et at Publishers (Kluwer & Narosa).

 

4.     Molecular pathogenesis of lung cancer (2002). In book: Some aspects of Chromosome

Structure and Function. pp 193-205 (Eds) Sobti, R.C. et at Publishers (Kluwer & Narosa).

 

 

 

Membership of national/International organization

  1. Member of clinical cytometry society (USA)

 

Honors/Awards:

Awarded Young Scientist Award from Panjab Academy of Sciences 2002

 

POSTER PRESENTATIONS/ORAL PRESENTATIONS/ABSTRACTS:

  1. XPD polymorphism and its association with lung cancer risk, overall survival and response in north Indian patients treated with platinum based chemotherapy. S. Lawania, S. Sharma, N. Singh, D. Behera. Poster presentation at 2nd Indian cancer congress 08 - 12 November, 2017  Bengaluru,
  2. Role of Polymorphic Variants of BER and DSBR Pathway Genes in Modulating Lung Cancer Susceptibility and Prognosis of North Indian Population” A. Singh, S. Sharma, N. Singh, D. Behera. Presented at IASLC 18TH WORLD CONFERENCE ON LUNG CANCER, October 15-18, 2017, Yokohama, Japan.
  3. UGT1A1 gene polymorphisms and clinical outcomes in small cell lung cancer (SCLC) patients treated with irinotecan-platinum chemotherapy: The first study from north India. Navneet Singh, Ankan Bandyopadhyay, Siddharth Sharma, Digambar Behera. Abstract presentation. 2017 American Association of clinical oncology (ASCO) Annual Meeting (June 2-6, 2017) Chicago, Illinois.
  4. Genetic variants in the Wnt antagonist genes (sFRP, Dkk and Axin2) predicts the overall survival and prognosis of North Indian lung cancer patients treated with platinum based doublet chemotherapy. Charu Bahl, Siddharth Sharma, Navneet Singh, Digambar Behera. Poster Presentation at CHASCON 2017 meeting9-11 March, 2017, Panjab University, Chandigarh
  5. Se-dietary matrices can upregulate the anti-inflammatory responses in RAW macrophages. Noorpreet Dhanjal Siddharth Sharma, Sandeep Prabhu Kumble, Tejo Prakash Nagaraja. Poster Presentation at 4th International Conference on Selenium in the Environment and Human Health. (18-21 October 2015, Sao Paulo, Brazil)
  6. Synergistic association of CHRNA5 (rs16969968) polymorphism towards increased susceptibility to squamous Cell Lung Cancer in North Indian Smokers. Yashila Girdhar, Siddharth Sharma, Navneet Singh, Digambar Behera. Oral Presentation at International Conference on Advances in Biomedical Engineering, cancer Biology, bioinformatics and applied biotechnology (ABECBAB) 25-26th July 2015, JNU, New Delhi.
  7. CyclinD1 polymorphism (G870A) in modifying susceptibility and overall survival of North Indian lung cancer patients. Ankita Pandey, Siddharth Sharma, Navneet Singh, Digambar Behera. Oral Presentation at International Conference on Advances in Biomedical Engineering, cancer Biology, bioinformatics and applied biotechnology (ABECBAB) 25-26th July 2015, JNU, New Delhi.
  8. Stem cell marker expression in cells from body cavity fluids. Awtar Krishan, Deepati Sharma, Siddharth Sharma, Ronald Hamelik, Parvin Ganjei-Azar, and Mehrdad Nadji. Presented at 24th Annual Meeting of the Clinical Cytometry Society October 16–18, 2009, Jacksonville, Florida, USA.
  9. Electronic Volume and ALDH expression in Stem cells from human Apheresis samples by Siddharth Sharma, Sherry Shariatmadar, Raquel Cabana, and Awtar Krishan. Presented at The 23rd Annual Meeting of the Clinical Cytometry Society October 12–14, 2008 Portland, Oregon, USA
  10. Electronic  Volume  of  Stem  Cells  in  Human  Apheresis  Samples  by  Siddharth Sharma, Raquel Cabana, Sherry Shariatmadar, Awtar Krishan. Presented at the ISAC XXIV International Congress, May 17-21, 2008 held at Budapest Hungary
  11. Electronic Cell Volume and Marker Expression in Stem Cells from Human Apheresis Samples by Siddharth Sharma, Raquel Cabana, Sherry Shariatmadar, Awtar Krishan. Presented at the AACR at San Diego, CA, USA on April12-16 2008.
  12. Electronic  Volume  of  Hematopoietic  Stem  Cells  by  Siddharth  Sharma,  Raquel Cabana, Sherry Shariatmadar, Awtar Krishan. Presented at the 22nd  Annual Clinical Cytometry society at Washington D.C. on October 16-19 2007.
  13. “P450-BIOCHIPS by Siddharth Sharma Natasha Beeton and JM Blackburn. Presented at the international conference on “A Molecular Meander in the Midlands” organized by South African Society for Biochemistry and Molecular Biology at PeiterMaritzburg, South Africa, on July 3-56h, 2006.

INVITED LECTURE

  • Guest lecture on “Flow cytometry and its role in modern biology” delivered to department of biotechnology GGDSD College, Chandigarh 11th of November 2017.
  • Guest speaker on “Flow cytometry and its clinical applications” in 49th Annual Conference of Indian Pharmacological Society (IPSCON-2016), India Scheduled on 20th to 23rd October 2016.